// App-Quantinova.ai

2787 : Long-Term Follow-up of Ongoing Patients in 2 Studies of Omacetaxine Mepesuccinate for Chronic Myeloid Leukemia.

Researchers

Presenter

  • Jeffrey H. Lipton

Principal Investigators

  • Michele Baccarani

  • Franck E. Nicolini

  • Meir Wetzler

  • Luke Akard

  • Laurence Legros

  • Krzysztof Warzocha

  • Adam Craig

  • Jorge E. Cortes

Medical Centers

  • Institute of Hematology and Transfusion Medicine, Warsaw, Poland

  • Centre Hospitalier Lyon-Sud, Pierre-Benite, France

  • Hopital Archet 2, Nice, France

  • Princess Margaret Hospital, Toronto, ON, Canada

Locations

  • Poland

  • Canada

  • France

  • Italy

Companies

  • Teva Pharmaceutical

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Chronic Myelogenous Leukemia

  • Thrombocytopenia

  • Neutropenia

  • Anemia

Biomarkers

  • N/A

Drug/Treatment

  • Omacetaxine mepesuccinate

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • open label

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved